- Home
- GNFT vs SGHT Comparison
GNFT vs SGHT Comparison
Compare GNFT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- SGHT
- Stock Information
- Founded
- GNFT 1999
- SGHT 2011
- Country
- GNFT France
- SGHT United States
- Employees
- GNFT N/A
- SGHT N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- SGHT Medical Specialities
- Sector
- GNFT Health Care
- SGHT Health Care
- Exchange
- GNFT Nasdaq
- SGHT Nasdaq
- Market Cap
- GNFT 296.4M
- SGHT 304.4M
- IPO Year
- GNFT 2019
- SGHT 2021
- Fundamental
- Price
- GNFT $3.83
- SGHT $3.90
- Analyst Decision
- GNFT Strong Buy
- SGHT Buy
- Analyst Count
- GNFT 1
- SGHT 7
- Target Price
- GNFT $13.00
- SGHT $6.27
- AVG Volume (30 Days)
- GNFT 7.6K
- SGHT 222.1K
- Earning Date
- GNFT 09-19-2024
- SGHT 11-07-2024
- Dividend Yield
- GNFT N/A
- SGHT N/A
- EPS Growth
- GNFT N/A
- SGHT N/A
- EPS
- GNFT 0.47
- SGHT N/A
- Revenue
- GNFT $86,225,222.00
- SGHT $79,543,000.00
- Revenue This Year
- GNFT $155.44
- SGHT $2.18
- Revenue Next Year
- GNFT N/A
- SGHT $8.14
- P/E Ratio
- GNFT $8.03
- SGHT N/A
- Revenue Growth
- GNFT 175.45
- SGHT N/A
- 52 Week Low
- GNFT $3.31
- SGHT $2.93
- 52 Week High
- GNFT $6.42
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- GNFT 26.67
- SGHT 40.94
- Support Level
- GNFT $3.89
- SGHT $3.65
- Resistance Level
- GNFT $4.06
- SGHT $4.12
- Average True Range (ATR)
- GNFT 0.12
- SGHT 0.19
- MACD
- GNFT 0.00
- SGHT 0.07
- Stochastic Oscillator
- GNFT 8.82
- SGHT 31.25
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.